Association between albumin-to-globulin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study
Abstract Objective Researches about the association between serum albumin-to-globulin ratio (AGR) and the prognosis of lung cancer are limited. We aimed to investigate the relationship between AGR and overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC) treated with anl...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-023-02574-6 |
| _version_ | 1797769689777045504 |
|---|---|
| author | Jinzhan Chen Congyi Xie Yimin Yang Shuwen Yang Jinxian Huang Feiyang Ye Zhenyang Lin Lin Tong Jiaxin Liu |
| author_facet | Jinzhan Chen Congyi Xie Yimin Yang Shuwen Yang Jinxian Huang Feiyang Ye Zhenyang Lin Lin Tong Jiaxin Liu |
| author_sort | Jinzhan Chen |
| collection | DOAJ |
| description | Abstract Objective Researches about the association between serum albumin-to-globulin ratio (AGR) and the prognosis of lung cancer are limited. We aimed to investigate the relationship between AGR and overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC) treated with anlotinib. Methods A retrospective cohort study was conducted on 196 advanced NSCLC patients with anlotinib treatment between June 1, 2018 and June 1, 2021. The exposure was AGR, calculated by baseline serum albumin / (serum total protein - serum albumin). The outcome was OS, defined as the period from the date of initial treatment with anlotinib to death or the last follow-up. The univariate and multivariate linear regression models and generalized additive models (GAM) were used to analyze the relationship between AGR and OS. The Kaplan-Meier method was used to analyze the OS. Results After adjusting for potential confounders, a non-linear relationship was observed between AGR and OS, which had an inflection point of 1.24. The hazard ratio and the confidence intervals on the left and the right sides of the inflection point were 13.05 (0.52 to 327.64) and 0.20 (0.07 to 0.57), respectively. It suggested that AGR was positively associated with OS when AGR was larger than 1.24, for every 1 unit increase in AGR, the risk of death lowered approximately by 80%. Conclusions The relationship between AGR and the OS for advanced NSCLC patients with anlotinib is non-linear. AGR level is an independent protective factor for OS in advanced NSCLC patients who received anlotinib therapy. |
| first_indexed | 2024-03-12T21:11:38Z |
| format | Article |
| id | doaj.art-22b65311ee044d8b95d8d16da1727e5b |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-03-12T21:11:38Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-22b65311ee044d8b95d8d16da1727e5b2023-07-30T11:06:22ZengBMCBMC Pulmonary Medicine1471-24662023-07-0123111010.1186/s12890-023-02574-6Association between albumin-to-globulin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort studyJinzhan Chen0Congyi Xie1Yimin Yang2Shuwen Yang3Jinxian Huang4Feiyang Ye5Zhenyang Lin6Lin Tong7Jiaxin Liu8Department of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan UniversityDepartment of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan UniversityDepartment of Vascular Surgery, Zhongshan Hospital, Fudan UniversityDepartment of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan UniversityDepartment of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan UniversityCollege of Computer and Data Science, Fuzhou UniversityDepartment of Thoracic Surgery, Zhongshan Hospital (Xiamen), Fudan UniversityDepartment of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan UniversityDepartment of Pulmonary Medicine, Zhongshan Hospital (Xiamen), Fudan UniversityAbstract Objective Researches about the association between serum albumin-to-globulin ratio (AGR) and the prognosis of lung cancer are limited. We aimed to investigate the relationship between AGR and overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC) treated with anlotinib. Methods A retrospective cohort study was conducted on 196 advanced NSCLC patients with anlotinib treatment between June 1, 2018 and June 1, 2021. The exposure was AGR, calculated by baseline serum albumin / (serum total protein - serum albumin). The outcome was OS, defined as the period from the date of initial treatment with anlotinib to death or the last follow-up. The univariate and multivariate linear regression models and generalized additive models (GAM) were used to analyze the relationship between AGR and OS. The Kaplan-Meier method was used to analyze the OS. Results After adjusting for potential confounders, a non-linear relationship was observed between AGR and OS, which had an inflection point of 1.24. The hazard ratio and the confidence intervals on the left and the right sides of the inflection point were 13.05 (0.52 to 327.64) and 0.20 (0.07 to 0.57), respectively. It suggested that AGR was positively associated with OS when AGR was larger than 1.24, for every 1 unit increase in AGR, the risk of death lowered approximately by 80%. Conclusions The relationship between AGR and the OS for advanced NSCLC patients with anlotinib is non-linear. AGR level is an independent protective factor for OS in advanced NSCLC patients who received anlotinib therapy.https://doi.org/10.1186/s12890-023-02574-6Lung cancerAnlotinibAlbuminGlobulinOverall survival |
| spellingShingle | Jinzhan Chen Congyi Xie Yimin Yang Shuwen Yang Jinxian Huang Feiyang Ye Zhenyang Lin Lin Tong Jiaxin Liu Association between albumin-to-globulin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study BMC Pulmonary Medicine Lung cancer Anlotinib Albumin Globulin Overall survival |
| title | Association between albumin-to-globulin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study |
| title_full | Association between albumin-to-globulin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study |
| title_fullStr | Association between albumin-to-globulin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study |
| title_full_unstemmed | Association between albumin-to-globulin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study |
| title_short | Association between albumin-to-globulin ratio and the risk of overall survival in advanced non-small cell lung cancer patients with anlotinib treatment: a retrospective cohort study |
| title_sort | association between albumin to globulin ratio and the risk of overall survival in advanced non small cell lung cancer patients with anlotinib treatment a retrospective cohort study |
| topic | Lung cancer Anlotinib Albumin Globulin Overall survival |
| url | https://doi.org/10.1186/s12890-023-02574-6 |
| work_keys_str_mv | AT jinzhanchen associationbetweenalbumintoglobulinratioandtheriskofoverallsurvivalinadvancednonsmallcelllungcancerpatientswithanlotinibtreatmentaretrospectivecohortstudy AT congyixie associationbetweenalbumintoglobulinratioandtheriskofoverallsurvivalinadvancednonsmallcelllungcancerpatientswithanlotinibtreatmentaretrospectivecohortstudy AT yiminyang associationbetweenalbumintoglobulinratioandtheriskofoverallsurvivalinadvancednonsmallcelllungcancerpatientswithanlotinibtreatmentaretrospectivecohortstudy AT shuwenyang associationbetweenalbumintoglobulinratioandtheriskofoverallsurvivalinadvancednonsmallcelllungcancerpatientswithanlotinibtreatmentaretrospectivecohortstudy AT jinxianhuang associationbetweenalbumintoglobulinratioandtheriskofoverallsurvivalinadvancednonsmallcelllungcancerpatientswithanlotinibtreatmentaretrospectivecohortstudy AT feiyangye associationbetweenalbumintoglobulinratioandtheriskofoverallsurvivalinadvancednonsmallcelllungcancerpatientswithanlotinibtreatmentaretrospectivecohortstudy AT zhenyanglin associationbetweenalbumintoglobulinratioandtheriskofoverallsurvivalinadvancednonsmallcelllungcancerpatientswithanlotinibtreatmentaretrospectivecohortstudy AT lintong associationbetweenalbumintoglobulinratioandtheriskofoverallsurvivalinadvancednonsmallcelllungcancerpatientswithanlotinibtreatmentaretrospectivecohortstudy AT jiaxinliu associationbetweenalbumintoglobulinratioandtheriskofoverallsurvivalinadvancednonsmallcelllungcancerpatientswithanlotinibtreatmentaretrospectivecohortstudy |